August 21, 2014 7:40 AM ET

Pharmaceuticals

Company Overview of HemaQuest Pharmaceuticals, Inc.

Company Overview

HemaQuest Pharmaceuticals, Inc., a pharmaceutical company, develops small molecule therapeutics based on its short chain fatty acid derivative (SCFAD) technologies to treat anemia and other blood disorders. Its products include Hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia; and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was formerly known as Hemagenex Pharmaceuticals, Inc. and changed its name in 2008. HemaQuest Pharmaceuticals, Inc. was founded in 2007 and is based in San Diego, California.

11995 El Camino Real

Suite 302

San Diego, CA 92130

United States

Founded in 2007

Phone:

858-356-5590

Fax:

858-356-5579

Key Executives for HemaQuest Pharmaceuticals, Inc.

Chief Executive Officer
Age: 67
Co-Founder and Director
Scientific Founder and Consultant
Co-Founder and Consultant
Age: 62
Co-Founder
Compensation as of Fiscal Year 2014.

HemaQuest Pharmaceuticals, Inc. Key Developments

HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2b Clinical Study of HQK-1001 in Patients with Sickle Cell Disease

HemaQuest Pharmaceuticals, Inc. announced that it has completed enrollment in a randomized, double-blind, placebo-controlled Phase 2b study of HQK-1001 in patients with sickle cell disease. The study, initiated in July 2012, enrolled a total of 77 patients in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon. HemaQuest expects an interim analysis of the study in late 2013 and final results in mid-2014. The Phase 2b study was designed to evaluate the efficacy, safety and tolerability of HQK-1001, a small chain fatty acid derivative administered orally twice daily. The primary objective of the study is the induction of fetal hemoglobin measured as an increase from baseline over time. Secondary objectives include the effect on frequency of pain crises, frequency and intensity of daily pain, analgesic use, and quality of life. HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory. HQK-1001 is an orally administered SCFAD which has been assessed in a number of clinical trials in sickle cell disease and beta thalassemia. These trials have established a safe and well tolerated dose which results in the induction of fetal hemoglobin. Induction of fetal hemoglobin production in red blood cells has been shown to reduce the frequency of pain crises and hospitalizations of patients with sickle cell disease. The compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia.

Similar Private Companies By Industry

Company Name Region
Cera Products, Inc. United States
Pfizer Pharmaceuticals Inc. United States
Cmxtwenty United States
Regional Nuclear Pharmaceuticals Inc. United States
Intervet Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HemaQuest Pharmaceuticals, Inc., please visit www.hemaquest.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.